Model systems to Assess The in vitro efficacy of CFTR modulator tHerapies in Cystic Fibrosis (MATCH-CF), Canada

Registration Status: Completed

Objective: Mutation-specific therapies that target the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein, referred to as CFTR modulators, have contributed to improvements in lung function, quality of life, and survival for people living with CF (PwCF). However, a minority of PwCF fail to show any clinical improvements when taking currently available therapies or are ineligible due to their rare genotypes. Our goal is to develop in vitro assays to predict individual clinical response to CFTR modulators. To achieve this goal, we will: 1- Obtain renewable and long-living cells from individuals with CF 2- Develop and optimize in vitro model systems from patient-derived cells 3- Test existing and future mutation-specific therapies on the cell-based model systems 4- Monitor individual short- and long-term clinical response to mutation-specific therapies

Registered Biobank Name Model systems to Assess The in vitro efficacy of CFTR modulator tHerapies in Cystic Fibrosis (MATCH-CF)
Biobank Leader Dr. Bradley Quon
Country Canada
Email for biobank inquiries bradley.quon@hli.ubc.ca
Principal Investigator Dr. Bradley Quon
Website
User Type
  • Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties
  • Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group
  • Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper
Biospecimen Collected:
Cohort Highlights